The drug development pipeline is key to bringing new therapies to people with Parkinson’s disease (PD). With major breakthroughs in research in the past year, including a new biomarker for PD, The Michael J. Fox Foundation’s Parkinson’s Progression Markers Initiative (PPMI) study and other initiatives can be leveraged to create better designed trials. This audio from our Third Thursdays Webinar features a conversation about all the ways clinical trial design is changing, and why leaders in the space believe those changes will lead to better treatments. The webinar includes contributions from a person with PD, a researcher and an industry leader.     

Like our podcasts? Please consider leaving a rating or review and sharing the series with your network. https://apple.co/3p02Jw0   

Whether you have Parkinson’s or not, you can help move research forward. Join the study that’s changing everything. Find out more at michaeljfox.org/podcast-ppmi.